Cargando…
Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474269/ https://www.ncbi.nlm.nih.gov/pubmed/34589922 http://dx.doi.org/10.1016/j.jtocrr.2020.100009 |
| _version_ | 1784575174681559040 |
|---|---|
| author | Jiang, Wei Guan, Ruting Shao, Yang W. Wang, Bo Wang, Yina |
| author_facet | Jiang, Wei Guan, Ruting Shao, Yang W. Wang, Bo Wang, Yina |
| author_sort | Jiang, Wei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8474269 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84742692021-09-28 Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib Jiang, Wei Guan, Ruting Shao, Yang W. Wang, Bo Wang, Yina JTO Clin Res Rep Case Report Elsevier 2020-02-11 /pmc/articles/PMC8474269/ /pubmed/34589922 http://dx.doi.org/10.1016/j.jtocrr.2020.100009 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Case Report Jiang, Wei Guan, Ruting Shao, Yang W. Wang, Bo Wang, Yina Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title | Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title_full | Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title_fullStr | Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title_full_unstemmed | Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title_short | Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib |
| title_sort | clinical benefit from a combination of brigatinib and camrelizumab in sarcomatoid transformation of alk-rearranged squamous cell lung cancer resistant to crizotinib |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474269/ https://www.ncbi.nlm.nih.gov/pubmed/34589922 http://dx.doi.org/10.1016/j.jtocrr.2020.100009 |
| work_keys_str_mv | AT jiangwei clinicalbenefitfromacombinationofbrigatinibandcamrelizumabinsarcomatoidtransformationofalkrearrangedsquamouscelllungcancerresistanttocrizotinib AT guanruting clinicalbenefitfromacombinationofbrigatinibandcamrelizumabinsarcomatoidtransformationofalkrearrangedsquamouscelllungcancerresistanttocrizotinib AT shaoyangw clinicalbenefitfromacombinationofbrigatinibandcamrelizumabinsarcomatoidtransformationofalkrearrangedsquamouscelllungcancerresistanttocrizotinib AT wangbo clinicalbenefitfromacombinationofbrigatinibandcamrelizumabinsarcomatoidtransformationofalkrearrangedsquamouscelllungcancerresistanttocrizotinib AT wangyina clinicalbenefitfromacombinationofbrigatinibandcamrelizumabinsarcomatoidtransformationofalkrearrangedsquamouscelllungcancerresistanttocrizotinib |